Overview
I am a physician-scientist with a background in medical oncology and neuro-oncology, with affiliations to multiple departments, research, and training programs at Duke.
I lead a Tumor Immunobiology Laboratory where we use various wet and dry lab techniques to understand the interactions between tumors and the immune system. Our goal is to identify vulnerabilities that can be targeted for novel therapies.
I serve as the Deputy Director of the Center for Cancer Immunotherapy at the Duke Cancer Institute where we are tasked to facilitate clinical research and translate promising discoveries made by scientists across various departments and cancer types at Duke, particularly in the field of immune and T cell-based therapies.
My team and our laboratory operate in an environment that enables the transition from bench-side basic scientific discoveries to clinical trials, and back to the bench ensuring the evaluation of new treatments for cancer patients.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.
Journal Article Neuro-oncology · February 2025 Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in patients with malignant gliomas have shown some early promise in pediatric and adult patients. However, the long-term benefits and safety for patients remain to be established. Th ... Full text CiteImmune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.
Journal Article J Neurooncol · February 2025 Glioblastoma (GBM), the most common and aggressive primary central nervous system (CNS) tumor in adults, continues to have a dismal prognosis. Across hundreds of clinical trials, few novel approaches have translated to clinical practice while survival has ... Full text Link to item CiteLeptomeningeal metastatic disease: new frontiers and future directions.
Journal Article Nat Rev Clin Oncol · February 2025 Leptomeningeal metastatic disease (LMD), encompassing entities of 'meningeal carcinomatosis', neoplastic meningitis' and 'leukaemic/lymphomatous meningitis', arises secondary to the metastatic dissemination of cancer cells from extracranial and certain int ... Full text Link to item CiteRecent Grants
Glioblastoma Immunotherapy Advancement with Nivolumab and Relatlimab
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2024 - 2029A Phase 2, multicenter, open label, two parts clinical study to evaluate the efficacy and safety of AB-218 in patients with isocitrate dehydrogenase 1 (IDH1) mutant glioma
Clinical TrialPrincipal Investigator · Awarded by AnHeart Therapeutics, Inc. · 2023 - 2028NUTMEG Tissue Analysis
ResearchPrincipal Investigator · Awarded by University of Sydney · 2022 - 2028View All Grants